Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for NextCure, Inc. (NXTC : NSDQ)

• Company Description    NextCure Inc. is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company's product candidate consists of NC318 and NC410 which are in clinical stage. NextCure Inc. is based in Beltsville, Maryland. Number of Employees: 40

• Price / Volume Information    Yesterday's Closing Price: $7.82 Daily Weekly Monthly 20 Day Moving Average: 147,812 shares Shares Outstanding: 3.61 (millions) Market Capitalization: $28.25 (millions) Beta: 1.33 52 Week High: $15.74 52 Week Low: $1.55 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 14.33% 14.84% 12 Week 294.95% 286.54% Year To Date -44.89% -51.12%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 8000 Virginia Manor Road Suite 140 - BELTSVILLE,MD 20705 USA ph: 240-399-4900 fax: - ir@nextcure.com http://www.nextcure.com

• General Corporate Information    Officers Michael Richman - President and Chief Executive Officer David Kabakoff - Chairman Steven P. Cobourn - Chief Financial Officer Anne Borgman - Director Ellen G. Feigal - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 65343E207 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/04/26 Share - Related Items Shares Outstanding: 3.61 Most Recent Split Date: 7.00 (0.08:1) Beta: 1.33 Market Capitalization: $28.25 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.90 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/04/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.33 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 83.70% vs. Previous Quarter: 1.60% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - -154.62 03/31/26 - -186.96 12/31/25 - -152.90 ROA 06/30/26 - -100.19 03/31/26 - -124.62 12/31/25 - -109.17 Current Ratio 06/30/26 - 3.47 03/31/26 - 4.61 12/31/25 - 4.14 Quick Ratio 06/30/26 - 3.47 03/31/26 - 4.61 12/31/25 - 4.14 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - 3.36 03/31/26 - 7.41 12/31/25 - 9.97 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©